| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T355 |
0-119 |
Sentence |
denotes |
In addition to IFN cytokine therapy, interleukin cytokine therapy can enhance the effector functions of NK cells (158). |
| T356 |
120-254 |
Sentence |
denotes |
The use of whole, unmodified recombinant cytokines as a monotherapy has resulted in minimal success in humans in cancer immunotherapy. |
| T357 |
255-405 |
Sentence |
denotes |
The earliest cytokine therapies to gain FDA-approval were IFN-α and recombinant IL-2, approved for renal cell carcinoma and metastatic melanoma (187). |
| T358 |
406-527 |
Sentence |
denotes |
Although approved, they were limited by their in vivo half-life, marginal anti-tumor activity, and associated toxicities. |
| T359 |
528-814 |
Sentence |
denotes |
The next generation of cytokine therapies were created to address these issues by first improving their biological stability through pegylation and fusion to chaperone molecules and secondly improving their specificity by fusing cytokines with antibodies or intratumoral administration. |
| T360 |
815-934 |
Sentence |
denotes |
These advances in the field have allowed for the reassessment of the therapeutic potential of specific cytokines (187). |
